C&R Research Acquires EPSI Korea, Targeting the Asian Clinical Trial Market
C&R Research, Korea's leading contract research organization (CRO), recently announced that it has acquired EPSI Korea. This acquisition is interpreted as a strategic decision for C&R Research to expand its influence in the Asian market and strengthen its global competitiveness.
C&R Research is a company that specializes in managing and supporting clinical trials, which are essential in the drug development process. EPSI Korea, the newly acquired company, is known for its extensive experience and expertise in the global clinical trial field. The combination of the two companies is expected to enable the provision of more efficient and professional services.
In particular, this acquisition is expected to be a significant help in securing a leading position in the Asian clinical trial market. C&R Research plans to further strengthen cooperation with neighboring countries such as China and Japan by utilizing EPSI Korea's existing network and infrastructure. This is expected to attract more clinical trial projects from global pharmaceutical companies.
Experts analyze that this acquisition will serve as an opportunity to enhance the overall competitiveness of the Korean bio-industry. An official from C&R Research expressed their ambition to grow into a world-class clinical trial specialist by continuously strengthening their technological capabilities and actively exploring overseas markets.